StockData
COSCIENS Biopharma Inc. logo

COSCIENS Biopharma Inc. (CSCIF) stock

CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 20-F on Mar 25, 2026Score 1/30
$6.49+0.00 (0.00%)

Close on Oct 19, 2026Market cap $24.10MP/E –Yield –

COSCIENS Biopharma operating margin

Operating margin is operating income as a percentage of revenue.

COSCIENS Biopharma's operating margin for the twelve months ending Mar 31, 2026 was -98.8%. For fiscal 2025 it was -142.5%, against -190.7% the year before. The highest annual figure on record is 36.6% in fiscal 2018.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-142.5%+48.2
FY2024Dec 31, 2024-190.7%−125.9
FY2023Dec 31, 2023-64.8%−94.5
FY2022Dec 31, 202229.6%+194.5
FY2021Dec 31, 2021-164.8%−8.6
FY2020Dec 31, 2020-156.2%+1768.9
FY2019Dec 31, 2019-1925.2%−1961.8
FY2018Dec 31, 201836.6%+2536.5
FY2017Dec 31, 2017-2499.9%+735.7
FY2016Dec 31, 2016-3235.6%+3165.2
FY2015Dec 31, 2015-6400.7%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-38.7%+153.0
Q4 FY2025Dec 31, 2025-135.2%+57.7
Q3 FY2025Sep 30, 2025-156.6%+179.7
Q2 FY2025Jun 30, 2025-85.6%+75.1
Q1 FY2025Mar 31, 2025-191.7%−103.5
Q4 FY2024Dec 31, 2024-192.9%−25.2
Q3 FY2024Sep 30, 2024-336.3%−279.4
Q2 FY2024Jun 30, 2024-160.7%−80.6
Q1 FY2024Mar 31, 2024-88.2%+109.5
Q4 FY2023Dec 31, 2023-167.7%−304.1
Q3 FY2023Sep 30, 2023-56.9%+143.1
Q2 FY2023Jun 30, 2023-80.0%+105.4
Q1 FY2023Mar 31, 2023-197.7%+129.8
Q4 FY2022Dec 31, 2022136.4%+331.4
Q3 FY2022Sep 30, 2022-200.1%−63.8
Q1 FY2022Mar 31, 2022-185.4%−105.8
Q4 FY2021Dec 31, 2021-327.5%−274.7
Q3 FY2021Sep 30, 2021-195.1%+1164.3
Q2 FY2021Jun 30, 2021-136.3%+1979.9
Q1 FY2021Mar 31, 2021-79.7%+37.6
Q4 FY2020Dec 31, 2020-52.8%+9741.7
Q3 FY2020Sep 30, 2020-1359.4%−720.5
Q2 FY2020Jun 30, 2020-2116.2%−191.9
Q1 FY2020Mar 31, 2020-117.2%+7823.3
Q4 FY2019Dec 31, 2019-9794.4%−9576.0
Q3 FY2019Sep 30, 2019-638.9%−184.7
Q2 FY2019Jun 30, 2019-1924.2%+161.5
Q1 FY2019Mar 31, 2019-7940.5%–
Q4 FY2018Dec 31, 2018-218.5%–
Q3 FY2018Sep 30, 2018-454.1%–
Q2 FY2018Jun 30, 2018-2085.7%–

More COSCIENS Biopharma figures

See a number that looks wrong?